Multiomics Identification of Radioresistance-Associated Biomarkers and Prognostic Model Construction in Rectal Cancer.
Summary
This multiomics study aimed to identify radioresistance biomarkers and construct a prognostic model for rectal cancer. Utilizing bulk and single-cell RNA-seq data from multiple cohorts, a risk score model based on radiotherapy-related genes was developed. This score demonstrated significant associations with immune cell infiltration and chemotherapy drug sensitivity. Five key genes potentially linked to radiotherapy sensitivity were identified and validated through protein expression and immunohistochemical analyses. These genes could serve as novel biomarkers for diagnosis, prognostic evaluation, and clinical management of rectal cancer.
Analysis
The identification of radioresistance biomarkers and the development of a prognostic model are crucial for optimizing rectal cancer management. These findings could enable more precise patient stratification, helping to predict radiotherapy response and personalize therapeutic strategies. This has the potential to improve treatment efficacy, reduce unnecessary toxicity, and guide the development of new therapeutic targets for radioresistant patients, paving the way for precision medicine.